Pharming Group N.V. cash flow statement

In fiscal 2025, Pharming Group N.V.'s operations generated $54.7m of cash; it spent $749,000 on capital projects, leaving free cash flow of $54.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pharming Group N.V.: cash flow statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	74	84	38	22	−17	−2	55
Depreciation and amortisation	5	6	2	2	2	2	1
Stock-based pay	4	7	9	6	9	11	14
Capital spending	3	5	11	1	1	1	1
Free cash flow	72	79	27	21	−19	−3	54
Free cash flow after stock pay	67	72	18	15	−28	−14	40

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: PHAR vs SVA MNKD vs PHAR MGTX vs PHAR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pharming Group N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pharming Group N.V.